XLO - NASDAQ
Xilio Therapeutics, Inc.
$8.46
-0.71%Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotXilio Therapeutics, Inc. Management Team
Scott Coleman
Chief Development Officer
Christopher Frankenfield
Chief Financial Officer & Chief Operating Officer
Compensation
$786,196
Nathan McBride
Chief Information Officer
Caroline Hensley
Chief Legal Officer
Katarina Luptakova
Chief Medical Officer
Compensation
$661,890
Uli Bialucha
Chief Scientific Officer
Rene Russo
President, Chief Executive Officer & Director
Compensation
$966,228
Kevin Brennan
Senior Vice President of Finance & Accounting
Ruth du Moulin
Senior Vice President of Medical Affairs
Xilio Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $118K and sold $6K worth of XLO shares, resulting in $113K of net buying activity.
3 Months
5.0K
43.95K
0
0.00
+44K
+$44K
3-6 Months
3.7M
373.00
8.9K
5.70K
-5K
-$5K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
13.4M
74.10K
0
0.00
+74K
+$74K
Top Buyers
Shannon James Samuel
Director
$92K
Russo Rene
Director, Officer: President And Ceo
$25K
Gilead Sciences, Inc.
10 Percent Owner
$2K
Top Sellers
Frankenfield Christopher James
Officer: Chief Financial Officer
$5K
Brennan Kevin M.
Officer: Svp, Finance And Accounting
$1K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $113K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
XLO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 26, 2026 | February 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | October 20, 2025 | November 21, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 25, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2022 | June 09, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.